Scarica l'app Stockscreener
96.93
0.31%
0.30
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRUS Giù?
Forum
Previsione
Precedente Chiudi:
$96.63
Aprire:
$96.8
Volume 24 ore:
708.20K
Relative Volume:
0.30
Capitalizzazione di mercato:
$7.35B
Reddito:
$35.93M
Utile/perdita netta:
$-244.56M
Rapporto P/E:
-24.54
EPS:
-3.95
Flusso di cassa netto:
$-157.31M
1 W Prestazione:
+0.82%
1M Prestazione:
+0.93%
6M Prestazione:
+75.00%
1 anno Prestazione:
+133.85%
Intervallo 1D:
$96.80
$96.94
Intervallo di 1 settimana:
$96.11
$96.94
Portata 52W:
$33.19
$96.94
Merus N V Stock (MRUS) Company Profile
Nome
Merus N V
Settore
Industria
Telefono
31 030 253 8800
Indirizzo
YALELAAN 62, 3584 CM UTRECHT
Confronta MRUS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
96.93 | 7.33B | 35.93M | -244.56M | -157.31M | -3.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-08-25 | Iniziato | Alliance Global Partners | Buy |
| 2025-02-13 | Iniziato | Piper Sandler | Overweight |
| 2025-02-07 | Iniziato | Wells Fargo | Overweight |
| 2024-11-21 | Iniziato | Goldman | Buy |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-03-28 | Iniziato | Truist | Buy |
| 2024-03-04 | Reiterato | Needham | Buy |
| 2023-11-02 | Iniziato | Canaccord Genuity | Buy |
| 2023-08-21 | Iniziato | TD Cowen | Outperform |
| 2022-08-02 | Iniziato | Stifel | Buy |
| 2022-02-11 | Iniziato | BMO Capital Markets | Outperform |
| 2022-02-10 | Iniziato | Needham | Buy |
| 2021-11-17 | Ripresa | Guggenheim | Buy |
| 2021-06-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-04-08 | Iniziato | William Blair | Outperform |
| 2021-03-16 | Iniziato | SVB Leerink | Outperform |
| 2020-06-26 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-27 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-20 | Ripresa | Guggenheim | Buy |
| 2019-06-28 | Iniziato | ROTH Capital | Buy |
| 2019-04-12 | Ripresa | Guggenheim | Buy |
| 2019-04-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-03-27 | Iniziato | Berenberg | Buy |
| 2018-01-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-03-21 | Downgrade | Citigroup | Buy → Neutral |
| 2016-12-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2016-11-07 | Downgrade | Citigroup | Buy → Neutral |
| 2016-06-13 | Iniziato | Citigroup | Buy |
| 2016-06-13 | Iniziato | Guggenheim | Buy |
| 2016-06-13 | Iniziato | Wedbush | Outperform |
Mostra tutto
Merus N V Borsa (MRUS) Ultime notizie
Boothbay Fund Management LLC Grows Holdings in Merus N.V. $MRUS - MarketBeat
Merus N.V. (NASDAQ:MRUS) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Genmab completes $6.9 billion acquisition of Merus N.V., triggers leadership changes - Investing.com Nigeria
Merus Acquired by Genmab, Leadership Changes Announced - TipRanks
Genmab Completes Acquisition of Merus N.V. to Bolster Oncology Portfolio - TipRanks
Genmab Finalizes Tender Offer for Dutch Biotech Merus - marketscreener.com
Genmab Completes Acquisition of Merus – Bolsters Portfolio with New Cancer Treatment - marketscreener.com
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period - The AI Journal
Genmab: Completion of Tender Offer for Outstanding Common Shares of Merus N.V. - marketscreener.com
Genmab: Completion Of Tender Offer For Outstanding Common Shares Of Merus N.V. - TradingView — Track All Markets
Genmab Announces Completion of Tender Offer for Outstanding - GlobeNewswire
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period - GlobeNewswire Inc.
Merus (NASDAQ:MRUS) VP Sells $163,370.00 in Stock - MarketBeat
How Genmab’s US$2.5 Billion Debt-Funded Merus Deal and Lymphoma Data Will Impact Genmab (CPSE:GMAB) Investors - simplywall.st
HighVista Strategies LLC Purchases 34,723 Shares of Merus N.V. $MRUS - MarketBeat
32,269 Shares in Merus N.V. $MRUS Purchased by Russell Investments Group Ltd. - MarketBeat
Insider Moves: Merus Executive Sells Significant Stock Holdings - TipRanks
(MRUS) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Genmab: How Its Combined Pipeline, Royalties & M&A Strategy Could Potentially Unlock A SOLID Upside! - Smartkarma
Stempoint Capital LP Cuts Holdings in Merus N.V. $MRUS - MarketBeat
Merus Shareholders Approve Genmab Acquisition Proposal - TipRanks
Merus shareholders approve Genmab acquisition proposal - MSN
Merus (NASDAQ:MRUS) Reaches New 12-Month HighTime to Buy? - MarketBeat
Merus NV stock hits all-time high at 96.29 USD By Investing.com - Investing.com Canada
Merus NV stock hits all-time high at 96.29 USD - Investing.com
How Genmab’s US$2.5 Billion Merus Deal Financing Could Impact Genmab (CPSE:GMAB) Investors - Yahoo Finance
Federated Hermes Inc. Has $80.40 Million Holdings in Merus N.V. $MRUS - MarketBeat
Saturn V Capital Management LP Has $11.80 Million Stock Position in Merus N.V. $MRUS - MarketBeat
Is Merus N.V. (2GH) stock included in top ETFs2025 Bull vs Bear & Daily Market Momentum Tracking - Newser
Can Merus N.V. stock outperform in 2025 bull marketQuarterly Growth Report & Capital Efficient Trade Techniques - Newser
Merus N.V. (MRUS): A Bull Case Theory - Finviz
Why institutional investors increase stakes in Merus N.V. (2GH) stockTrade Ideas & Technical Pattern Based Signals - Newser
What makes Merus N.V. (2GH) stock appealing to growth investorsWeekly Trend Recap & High Conviction Buy Zone Picks - Newser
Genmab closes $2.5 billion notes offering to fund Merus acquisition - Investing.com
Genmab closes $2.5 billion notes offering to fund Merus acquisition By Investing.com - Investing.com South Africa
Sio Capital Management LLC Purchases Shares of 62,719 Merus N.V. $MRUS - MarketBeat
Merus (MRUS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Quadrature Capital Ltd Buys New Position in Merus N.V. $MRUS - MarketBeat
Will Merus N.V. (2GH) stock return to pre crash levelsWeekly Profit Recap & Daily Oversold Stock Bounce Ideas - Newser
Can Merus N.V. (2GH) stock hold up in economic slowdownMarket Performance Recap & Risk Controlled Swing Trade Alerts - Newser
Merus N.V. $MRUS Shares Acquired by Ensign Peak Advisors Inc - MarketBeat
What analysts say about Merus NV stockEarnings Volatility Patterns & Free Transform Portfolio With Stocks - earlytimes.in
Merus (NASDAQ:MRUS) VP Harry Shuman Sells 8,300 Shares - MarketBeat
Responsive Playbooks and the MRUS Inflection - news.stocktradersdaily.com
Merus N.V.: VP controller Shuman sells $796k in shares By Investing.com - Investing.com Australia
ETFs investiert in Merus N.V.-Aktien - TradingView
Major Stock Sale Shakes Up Merus! - TipRanks
Merus N.V.: VP controller Shuman sells $796k in shares - Investing.com
Finance Watch: Lilly Toes The $1 Trillion Valuation Line - Citeline News & Insights
Halozyme Therapeutics (HALO): Evaluating Valuation Following New ENHANZE Partnership With Merus - simplywall.st
Merus N V Azioni (MRUS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):